Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Jan 06, 2022 5:46am
84 Views
Post# 34288103

RE:RE:RE:GUD Announces Approval of Lenvima® in Columbia

RE:RE:RE:GUD Announces Approval of Lenvima® in Columbia
MrMugsy wrote: Just looked at the product roadmap GoldenInvestor ... Lenvima has already beein launched in "Argentina" and in "other" geographies. 

If I'm reading it correctly - Brazil will be launched first and eventually it will be launched in Columbia.

No other geographies planned for this drug.


MrMugsy, where did you see that info?

The Product Pipeline PDF on the website shows that Lenvima has been:

1) "Marketed" in Brazil
2) "Launched" in Argentina and Others.

An updated version would now show "Approved" for Colombia, of course.

From the Investor Presentation file we can also see "Pending approval in Colombia, Uruguay, Bolivia and Paraguay".

By the way, we should have Halaven approved in Colombia soon as well! :)
<< Previous
Bullboard Posts
Next >>